Trial
NCT05728372
64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Metastatic Malignant Solid Neoplasm
Intervention
Copper Cu 64-DOTA-pembrolizumab
Why stopped
withdrawn per PI
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-10